Hydroxyzine Tablets/Capsules

Hydroxyzine Tablets/Capsules

Form: Tablets/Capsules

Strength: 10 mg, 25 mg, 50 mg, 100 mg

Reference Brands: US: Vistaril®, , Atarax®; EU: Atarax®, Hydroxyzine Mylan®, Ucerax®

Category: Antipsychotropic Drugs

Hydroxyzine tablets and capsules are FDA-approved in the USA for treating anxiety, tension, pruritus, and for sedation. Widely prescribed in both adults and children, labeling emphasizes dose adjustments, CNS effects, and contraindications in patients with prolonged QT interval. In the European Union, hydroxyzine is authorized under national procedures, not centralized, with restrictions in some countries due to cardiac safety concerns. EU regulations mandate clear warnings on QT prolongation, drug interactions, and age-based contraindications. Pharmacovigilance measures, including risk minimization plans, are strictly enforced. For sourcing and detailed product listings, visit Pharmatradz.com.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Risperidone Long-Acting Injection

Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg vials/syringes

Form: Long-Acting Injection

Reference Brands: Risperdal Consta(US &EU)

View Details Get Enquiry
Zuclopenthixol ong-acting IM Injection (Depot)

Strength: 200 mg/mL, 500 mg/mL

Form: Long-acting IM Injection (Depot)

Reference Brands: Clopixol Depot®(US)

View Details Get Enquiry
Zuclopenthixol Short-acting Intramuscular Injection

Strength: 50 mg/mL

Form: Short-acting Intramuscular Injection

Reference Brands: Clopixol-Acuphase®

View Details Get Enquiry
Zuclopenthixol tablets

Strength: 10 mg, 25 mg, 40 mg

Form: Oral Tablets

Reference Brands: Clopixol®(EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

We use cookies to ensure you get the best experience. Learn more